ARK Genomic Revolution ETF (BATS:ARKG) Reaches New 12-Month High – Still a Buy?

ARK Genomic Revolution ETF (BATS:ARKG)’s share price reached a new 52-week high on Wednesday . The stock traded as high as $46.78 and last traded at $46.14, with a volume of 669417 shares. The stock had previously closed at $43.21.

ARK Genomic Revolution ETF Stock Down 0.2%

The company’s 50 day simple moving average is $40.52 and its 200 day simple moving average is $33.29.

Hedge Funds Weigh In On ARK Genomic Revolution ETF

Several institutional investors and hedge funds have recently made changes to their positions in the company. Ascentis Independent Advisors acquired a new stake in ARK Genomic Revolution ETF during the 1st quarter worth $26,000. PNC Financial Services Group Inc. increased its holdings in shares of ARK Genomic Revolution ETF by 53.2% in the first quarter. PNC Financial Services Group Inc. now owns 1,088 shares of the company’s stock worth $29,000 after acquiring an additional 378 shares in the last quarter. Sunbelt Securities Inc. raised its position in shares of ARK Genomic Revolution ETF by 734.3% during the third quarter. Sunbelt Securities Inc. now owns 1,118 shares of the company’s stock worth $31,000 after purchasing an additional 984 shares during the period. Western Wealth Management LLC bought a new position in shares of ARK Genomic Revolution ETF during the 1st quarter valued at about $37,000. Finally, Strategic Wealth Investment Group LLC acquired a new position in shares of ARK Genomic Revolution ETF in the 2nd quarter valued at approximately $38,000.

ARK Genomic Revolution ETF Company Profile

The ARK Genomic Revolution ETF (ARKG) is an exchange-traded fund that mostly invests in stocks based on a particular theme. The fund is an actively managed fund that targets companies involved in the genomics industry. ARKG was launched on Oct 31, 2014 and is managed by ARK.